Peter Frambach
YOU?
Author Swipe
View article: VARC-HBR criteria validation in TAVI patients on oral anticoagulation
VARC-HBR criteria validation in TAVI patients on oral anticoagulation Open
The VARC-HBR criteria effectively identified distinct subgroups with a stepwise increase in major bleeding post-TAVI. However, their predictive performance for individual risk was moderate.
View article: Continuation versus Interruption of Oral Anticoagulation during TAVI
Continuation versus Interruption of Oral Anticoagulation during TAVI Open
In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death f…
View article: Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial
Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial Open
About one-third of patients undergoing transcatheter aortic valve implantation (TAVI) use oral anticoagulants (OAC), mainly due to atrial fibrillation. General guidelines advise interrupting OAC in patients with a high risk of bleeding und…
View article: Titanium-Nitride-Oxide–Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome
Titanium-Nitride-Oxide–Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome Open
Importance Titanium-nitride-oxide (TiNO)–coated stents show faster strut coverage compared with drug-eluting stents without excessive intimal-hyperplasia observed in bare metal stents. It is important to study long-term clinical outcomes a…
View article: Long‐term follow‐up of contemporary drug‐eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial
Long‐term follow‐up of contemporary drug‐eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial Open
Objective The elevated risk of adverse events following percutaneous coronary intervention in diabetic patients persists with newer‐generation DES. The polymer‐free amphilimus‐eluting stent (PF‐AES) possesses characteristics with a potenti…
View article: Clinical outcomes after permanent polymer or polymer‐free stent implantation in patients with diabetes mellitus: The <scp>ReCre8</scp> diabetes substudy
Clinical outcomes after permanent polymer or polymer‐free stent implantation in patients with diabetes mellitus: The <span>ReCre8</span> diabetes substudy Open
Objectives The purpose of this analysis was to compare target‐lesion failure (TLF) of a permanent polymer zotarolimus‐eluting stent (PP‐ZES) versus a polymer‐free amphilimus‐eluting stent (PF‐AES) in diabetics. Background The improvement o…
View article: Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation Open
Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspi…
View article: Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation Open
In patients undergoing TAVI who were receiving oral anticoagulation, the incidence of serious bleeding over a period of 1 month or 1 year was lower with oral anticoagulation alone than with oral anticoagulation plus clopidogrel. (Funded by…
View article: A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aortic stenosis
A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aortic stenosis Open
The DFM-TAVS was associated with good short-term outcomes in this real-world registry. The low pacemaker and aortic regurgitation rates confirm the advantages of this next-generation transcatheter heart valve (THV).
View article: Real-world multicentre experience with the Direct Flow Medical® repositionable and retrievable transcatheter aortic valve implantation system for the treatment of high-risk patients with severe aortic stenosis
Real-world multicentre experience with the Direct Flow Medical® repositionable and retrievable transcatheter aortic valve implantation system for the treatment of high-risk patients with severe aortic stenosis Open
In a multicentre, real-world clinical setting of high-risk patients with severe aortic stenosis, a repositionable and retrievable TAVI system was effective and safe in the short-term follow-up.